

## ***Biological & Pharmaceutical Bulletin*** **Instructions for Authors**

The Journal will accept original and innovative submissions in English from both members and non-members of the Pharmaceutical Society of Japan, on the understanding that the work is unpublished and is not being considered for publication elsewhere.

### **TYPES OF MANUSCRIPT**

The Journal publishes Regular Articles, Notes, Communications, and Reviews. With the exception of Invited Reviews, manuscripts will be reviewed by two or more members of the editorial board, whose opinions will form the basis of the final decision by the editor.

It is recommended that an English check of the manuscript by a competent and knowledgeable native speaker be completed before submission. Only manuscripts that are written in clear and concise English will be accepted for review. For manuscripts whose English is judged by the Pharmaceutical Society of Japan to be of inadequate quality, English editing will be conducted with the cost to be paid by the author(s).

**1 Regular Articles:** New, significant, innovative, and original findings are suitable as Regular Articles.

**2 Notes:** Papers containing new facts and important data derived from incomplete or partial studies may be suitable as a Note. In general, a Note should not exceed 4 printed pages.

**3 Communications:** Communications should contain new and important information that would be of interest to readers of the Journal, making urgent publication is desirable. An explanatory statement is required for urgent publication. In general, a Communication should not exceed 2 printed pages. Please indicate in the cover letter the reason why the manuscript should be treated as a Communication.

#### **4 Reviews:**

1) Regular Reviews: Describing the research results of the author.

2) Invited Reviews: Reviews are submitted by invitation from the editorial board, and encompass recent important scientific discoveries.

### **SUBMISSION GUIDELINES**

The manuscript should be submitted as a PDF file using the "Online Submission" section in our Web site (<http://bpb.pharm.or.jp>).

### **MANUSCRIPT PREPARATION**

**1 Manuscript Form** A manuscript, including all figures and tables, should be contained in one PDF file. The text should be single-spaced and typed using Times New Roman 12 point font on A4-sized paper (297 mm×210 mm). There are approximately 30 lines per page and there should be a 2.5 cm margin on each side.

(Cover letter)

The cover letter should include information on the corresponding author (the corresponding author's name, affiliation and address, telephone/fax numbers, and e-mail address), and for non-native English speaking authors, the name of the native English speaker or company that checked the manuscript for correct English usage. For contributions from Japan, the corresponding author's name and address should be written in Japanese as well as English. (The cover letter should also be sent as a PDF file.)

**1) Title Page** The title page (page 1) should start with the journal name (Biol. Pharm. Bull.) and type of manuscript (Regular Article, Note, *etc.*). This should be followed by the appropriate section for the manuscript (*i.e.* Analytical Biochemistry, Biochemistry, Molecular and Cell Biology, Microbiology, Pharmacology, Medicinal Chemistry, Pharmacognosy, Biopharmacy, or Miscellaneous), the title, name(s) of the author(s) and affiliations, and mailing address. Please indicate the corresponding author's e-mail address in the footnote. An asterisk (\*) should be added to the right of the corresponding author's name. When there are two or more authors and they belong to more than one affiliation, the connection between each author and his or her affiliation should be indicated by italicized superscripts *a*, *b*, *c*... placed after each author's name and before each affiliation.

Examples for describing affiliations and mailing addresses:

<sup>a</sup> *Department of Molecular Biology, Graduate School of Pharmaceutical Sciences, Hokkaido University;* <sup>b</sup> *Faculty of Pharmaceutical Sciences, Hokkaido University; Kita 12, Nishi 6, Kita-ku, Sapporo 060-0812, Japan;* <sup>c</sup> *Institute for Genetic Medicine, Hokkaido University; Kita 15, Nishi 7, Kita-ku, Sapporo 060-0815, Japan;* and <sup>d</sup> *Graduate School of Agriculture, Hokkaido University; Kita 9, Nishi 9, Kita-ku, Sapporo 060-8589, Japan.*

**2) Summary and Keywords** Page 2 should contain a summary no longer than 250 words as well as 3 to 6 descriptive keywords, listed in decreasing order of importance. The first 3 keywords must be independent, as they will be used in a keyword combination in the index (less than 80 characters).

**3) Main Text** The text, acknowledgments, references, figure legends, tables, and figures should be presented in this

order. Figures, tables, and charts/diagrams showing chemical structures should be at the end, each on a separate page. All pages should be numbered consecutively.

**2 Figures, Tables, and Charts/Diagrams Showing Chemical Structures** Only one figure, table, or chart should appear on one page of an A4-sized paper (both portrait and landscape paper orientations can be used). Arabic numbers should be used for all compound numbers, figures, and tables (e.g. Fig. 1 and Table 1). The list of figure legends should appear on a separate page.

**3 Abbreviations** Abbreviations must be spelled out in full at their initial appearance, followed by the abbreviation in parentheses. Thereafter, the abbreviation only may be used. However, the following need not be defined: ADP (adenosine 5'-diphosphate), AIDS (acquired immunodeficiency syndrome), AMP (adenosine 5'-monophosphate or adenylic acid), ATP (adenosine 5'-triphosphate), cAMP (adenosine 3',5'-cyclic monophosphate), cDNA (complementary DNA), CoA (coenzyme A), DNA (deoxyribonucleic acid), ED<sub>50</sub> (50% effective dose), ESR (electron spin resonance), FAB-MS (fast atom bombardment mass spectrometry), FAD (flavin adenine dinucleotide), GC-MS (gas chromatography-mass spectrometry), GLC (gas-liquid chromatography), GMP (guanosine 5'-monophosphate), HPLC (high-performance liquid chromatography, high-pressure liquid chromatography), IC<sub>50</sub> (inhibitory concentration, 50%), IR (infrared), LC (liquid chromatography), LC/MS (liquid chromatography/mass spectrometry), LD<sub>50</sub> (50% lethal dose), mRNA (messenger RNA), MS (mass spectrum), NMR (nuclear magnetic resonance), P450 (as in cytochrome P450), RNA (ribonucleic acid), TLC (thin-layer chromatography), tRNA (transfer RNA), UV (ultraviolet spectrum)

**4 Units** The following units should be used: length (m, cm, mm,  $\mu\text{m}$ , nm, Å), mass (kg, g, mg,  $\mu\text{g}$ , ng, pg, mol, mmol), volume (l, ml,  $\mu\text{l}$ ), time (s, min, h, d), temperature ( $^{\circ}\text{C}$ , K), radiation (Bq, Ci, dpm, Gy, rad), and concentration (M, mM, mol/l, mmol/l, mg/ml,  $\mu\text{g}/\text{ml}$ , %, % (v/v), % (w/v), ppm, ppb)

**5 Spectral and Elemental Analysis Data** Please report spectral and elemental analysis data in the following format. <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 1.25 (3H, d,  $J=7.0$  Hz), 3.55 (1H, q,  $J=7.0$  Hz), 6.70 (1H, m). <sup>13</sup>C-NMR (CDCl<sub>3</sub>)  $\delta$ : 20.9 (q), 71.5 (d), 169.9 (s). IR (KBr)  $\text{cm}^{-1}$ : 1720, 1050, 910. UV  $\lambda_{\text{max}}$  (EtOH) nm ( $\epsilon$ ): 241 (10860), 288 (9380). UV  $\lambda_{\text{max}}$  (H<sub>2</sub>O) nm (log  $\epsilon$ ): 280 (3.25). FAB-MS  $m/z$ : 332.1258 (Calcd for C<sub>18</sub>H<sub>20</sub>O<sub>6</sub>: 332.1259). MS  $m/z$ : 332 (M<sup>+</sup>), 180, 168. [ $\alpha$ ]<sub>D</sub><sup>23</sup> -74.5 ( $c=1.0$ , MeOH). Anal. Calcd for C<sub>19</sub>H<sub>21</sub>NO<sub>3</sub>: C, 73.29; H, 6.80; N, 4.50. Found: C, 73.30; H, 6.88; N, 4.65.

**6 Nomenclature** The nomenclature used for chemical compounds shall be in accordance with the nomenclature rules formulated by IUPAC. Alternatively, naming may conform to the nomenclature in the index of *Chemical Abstracts* or the Ring Index.

**7 References and Notes** "References" include articles published in journals, books, on the Internet, and others (technical reports, patents, lectures, etc.). References other than those indicated above should be described in the text. References should be numbered consecutively according to their order of appearance in the text (one Arabic number should be assigned to one reference). An Arabic number followed by a parenthesis should be placed after the last relevant word and all references should be listed in numerical order at the end of the text in the section entitled References and Notes. The abbreviations for journals should conform to *Chemical Abstracts* (cf. The ACS Style Guide. A Manual for Authors and Editors).

Examples of references are as follows:

- 1) Roques B. P., Florentin D., Callanquin M., *J. Heterocycl. Chem.*, **12**, 195—196 (1975).
- 2) Cruickshank R., Duguid I. P., Marmion B. P., Swain R. H. A., "Medical Microbiology," 12th ed., Vol. III, Churchill Livingstone, New York, 1975.
- 3) Szejtli J., "Cyclodextrin Technology," ed. by Davis J. E. D., Kluwer Academic, Dordrecht, 1988.
- 4) Tokuda H., Ichiishi E., Onozuka M., Yamaguchi S., "Biology of Nitric Oxide, Part 6," Vol. I, Chap. 2, eds. by Moncada S., Tada N., Maeda H., Portland Press, London, 1998, pp. 185—186.
- 5) Frömring K.-H., Szejtli J.: (<http://www.bpb.com/>), PSJ Web, 25 November 1999.
- 6) Based on a lecture presented at the 30th Symposium on Heterocyclic Chemistry, Tokyo University of Pharmacy & Life Science, Hachioji, on 25 November 1999.

In the list of references in the References section, include the last names and initials of the first and middle names for all authors.

For references appearing in the main text, the last names of the first 2 authors only should be written. For references with 3 or more authors, write the name of the first author followed by *et al.* (Example: Jones A. B., *et al.*).

## X-RAY CRYSTAL STRUCTURE ANALYSES

When structure determination by X-ray crystallographic analysis is a central theme of a paper, the data required for registration with the Cambridge Crystallographic Data Centre (CCDC) should be attached as supplementary material. Although this does not apply in cases where crystallographic analysis plays only a supplementary role, crystal data (unit cell parameters, space group, Z density) and R-factor should still be noted. Atomic coordinates will be printed when the structure is important. Bond lengths and angles, thermal parameters, and torsion angles will be printed when they are important for the issues addressed in the paper. When papers have been accepted, the authors are advised to register the data with CCDC.

## NUCLEOTIDE SEQUENCES

Newly reported nucleotide sequences must be deposited in one of the data banks, (either DDBJ, GenBank, or EMBL) and an accession number must be obtained before the paper will be accepted by the Associate Editor's office. Access to the infor-

mation in the database must be available at the time of publication. A footnote will be included in the paper indicating that such a deposit has been made.

## ETHICS

1 For manuscripts dealing with scientific investigations involving human subjects and/or human tissues, the experiments should be performed in accordance with the ethical standards formulated in the Helsinki Declaration of 1964 (revised in 2004, <http://www.wma.net/e/policy/b3.htm>), while experiments dealing with the human genome should be conducted according to the Japanese government's "Ethical Standards for Human Genome and Genetic Analysis Research" ([http://www.mext.go.jp/a\\_menu/shinkou/seimei/genomeshishin](http://www.mext.go.jp/a_menu/shinkou/seimei/genomeshishin)). Furthermore, only studies that have been performed after receiving approval from the appropriate ethics committee of an institution will be accepted for publication. Finally, please clearly state in the manuscript that the study was performed according to these guidelines and attach to the manuscript a copy of the certificate from the ethics committee (a PDF file of the scanned certificate is acceptable for manuscripts that are submitted electronically).

2 Manuscripts describing animal experiments should be conducted in accordance with the experimental animal guidelines of the institution as well as the appropriate government guidelines, such as those published by the Japanese Ministry of Education, Culture, Sports, Science and Technology. Only manuscripts of experiments conducted in accordance with the appropriate guidelines will be eligible for publication. Finally, please state clearly within the manuscript which guidelines were followed and that the study was indeed conducted in accordance with the guidelines.

## PAGE CHARGES

Authors must pay a fee (page charge) for publication. The corresponding author will be informed of the page charge after publication of the manuscript in the *Biological & Pharmaceutical Bulletin*. The charges in the table below do not include consumption tax.

The Journal reserves the right to modify the charges without prior notification.

1 Page Charge: 4,000 Japanese yen per printed page.

2 Reprint Charges (Japanese yen)

Number of Pages Number of Reprints	Number of Pages					
	1~2	3~4	5~6	7~8	9~10	Greater than 11
50	¥8000	¥9000	¥10000	¥11000	¥12000	¥13000
100	¥14400	¥16200	¥18000	¥19800	¥21600	¥23400
150	¥19200	¥21600	¥24000	¥26400	¥28800	¥31200
200	¥22400	¥25200	¥28000	¥30800	¥33600	¥36400
More than 250	¥110 each	¥120 each	¥130 each	¥150 each	¥160 each	¥180 each

· Postage included; Tax extra.

· Reprints only available in multiples of 50.

· Color printing carries an extra surcharge of ¥80 per page.

· Cover charge: ¥30 each.

3 Actual cost for color figures.

4 Actual cost for English revision and editing.

5 The page charge should be paid, but is not a condition for publication, since the decision for publication is made on the basis of scientific significance only. The publication charge may be waived upon request from authors who do not have sufficient funds. No free reprints of the article will be provided in such cases.

## OTHER IMPORTANT POINTS

1 Please submit the revised manuscript to the appropriate person in the Editorial Office no later than two months from the date of notification of manuscript revision by the editor, by logging onto "Author Login" in "Online Submission." A manuscript that is submitted after the two-month period will be treated as a new submission.

2 When a manuscript is accepted for publication, soft copies of the text and tables (Microsoft Word file) and figures (TIFF or EPS format file, ChemDraw file, *etc.*) should be submitted to the Editorial Office.

3 The authors are given an opportunity to proofread the galley of an accepted manuscript. Galleys will be sent by airmail. No additions and revisions are allowed other than the correction of typographical errors.

4 The copyrights of all manuscripts published in the *Biological & Pharmaceutical Bulletin* belong to the Pharmaceutical Society of Japan. The author must submit a Copyright Transfer form to the Pharmaceutical Society of Japan.

5 Rejected manuscripts will not be returned to the author.